VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC Internation...( BASKING RIDGE N.J. Oct. 19 /- Vio...),Health

BASKING RIDGE, N.J., Oct. 19 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer therapeutics, announced today that it will be presenting data in poster presentations pertaining to VQD-002 (TCN-PM) and Lenocta(TM) (SSG) at the "Molecular Targets and Cancer Therapeutics" International Conference sponsored by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC) taking place October 22-26, 2007 at the Moscone Convention Center West in San Francisco, CA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )

VQD-002:

Abstract Number B71 titled, "Phase I pharmacokinetic and pharmacodynamic study of the inhibitor of activation of AKT (p-Akt), triciribine phosphate monohydrate (TCN-PM), in solid malignancies."

Session Title: Poster Session B

Session Subtitle: Clinical Trials

Session Date: Wednesday, October 24, 2007, 12:30 P.M. PDT

Session Time: 12:30-2:30 P.M. and 5:30-7:30 P.M. PDT

Session Location: Exhibit Hall, First Floor, Moscone Convention

Center West

Lenocta(TM)

Abstract Number B89 titled, "Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a protein tyrosine phosphatase inhibitor - in Combination with Interferon-alpha for patients with solid tumors."

Session Title: Poster Session B

Session Subtitle: Clinical Trials

Session Date: Wednesday, October 24, 2007, 12:30 P.M. PDT

Session Time: 12:30-2:30 PM and 5:30-7:30 P.M. PDT

Session Location: Exhibit Hall, First Floor, Moscone Convention

'/>"/>